In this free webinar, learn practical signal detection approaches that reduce placebo response and improve clinician-rated outcomes in major depressive disorderIn this free webinar, learn practical signal detection approaches that reduce placebo response and improve clinician-rated outcomes in major depressive disorder

Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn practical signal detection approaches that reduce placebo response and improve clinician-rated outcomes in major depressive disorder (MDD) clinical trials. Attendees will gain insight into how targeted rater preparation, guided questioning and consistent scoring practices contribute to reducing variability in clinician-administered assessments. The featured speakers will share approaches for reviewing site-generated data using combined statistical, algorithmic and expert-driven oversight to identify risk patterns earlier. Attendees will learn the ways centralized clinician scoring can reinforce uniform application of rating scales across sites. The speakers will share techniques for shaping participant expectations to promote more accurate self-report and clinician-rated outcomes. Attendees will also learn design considerations in eCOA systems that reduce common user errors and support cleaner, more reliable outcome data.

TORONTO, Dec. 17, 2025 /PRNewswire/ — Placebo response remains one of the most significant challenges in major depressive disorder (MDD) clinical trials, often obscuring actual treatment effects and delaying the approval of promising new therapies. Despite its widespread recognition, the placebo effect remains poorly understood. It refers to a measurable improvement in a participant’s condition following an inactive treatment and is particularly impactful in psychiatric trials where clinician-administered outcomes are central to study success. The subjective nature of these assessments, combined with rater variability and participant expectations, makes MDD trials especially vulnerable to elevated placebo response rates and inconsistent outcome signal detection.

This webinar is designed to help attendees improve the quality, reliability and interpretability of clinician-rated outcomes in MDD trials. Participants will gain foundational knowledge of the placebo effect, its origins, mechanisms and relevance to current trial design, while exploring modern, evidence-based strategies to minimize its impact. Through a combination of expert guidance, real-world case examples and practical tools, the session will focus on strengthening rater performance, reducing data variability and improving trial signal detection.

Training Objectives:

  • Explore methods to mitigate placebo response via rater-focused education and calibration, structured interview guides and specialized mitigation training
  • Examine central monitoring approaches, including algorithmic and data-based review, and risk-based expert analysis
  • Understand centralized rating and scoring models using trained clinicians
  • Identify best practices for managing participant expectations
  • Learn how eCOA design can prevent common rater errors before they impact data

Register for this webinar to learn practical signal detection approaches that reduce placebo response and improve clinician-rated outcomes in MDD clinical trials.

Join experts from Cogstate, Luka Lucić, PhD, Senior Director, Clinical Science, Psychiatry; and Svenja Wacker, PhD, Neuropsychology Science Director, for the live webinar on Wednesday, January 21, 2026, at 11am EST (5pm CET/EU-Central).

For more information, or to register for this event, visit Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit www.xtalks.com

For information about hosting a webinar visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/enhancing-signal-detection-and-mitigating-placebo-response-in-major-depressive-disorder-clinical-trials-upcoming-webinar-hosted-by-xtalks-302644245.html

SOURCE Xtalks

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.11346
$0.11346$0.11346
-2.61%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.